In Brief: Lunar/Hologic
This article was originally published in The Gray Sheet
Executive SummaryLunar/Hologic: Enter definitive agreement settling all disputes between the firms, Lunar says Nov. 22. "The agreement provides certain continuing payments between the parties related to future sales and an agreement not to engage each other in patent litigation in the area of x-ray densitometry and ultrasound for a 10-year period," the firm states. Earlier this fall, the firms announced that they had reached an "agreement in principle" to settle patent issues ("The Gray Sheet" Oct. 2, In Brief)...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.